Published in
American Association for the Advancement of Science, Science Translational Medicine, 388(9), 2017
DOI: 10.1126/scitranslmed.aaj1928
Links
Tools
A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants
Journal article published in 2017 by
Qing Zhu 
,
Jason S. McLellan ,
Nicole L. Kallewaard ,
Nancy D. Ulbrandt ,
Susan Palaszynski,
Jing Zhang,
Brian Moldt,
Anis Khan,
Catherine Svabek ,
Josephine M. McAuliffe ,
Daniel Wrapp ,
Nita K. Patel ,
Kimberly E. Cook,
Bettina W. M. Richter,
Patricia C. Ryan
and other authors.
,
Jason S. McLellan ,
Nicole L. Kallewaard ,
Nancy D. Ulbrandt ,
Susan Palaszynski,
Jing Zhang,
Brian Moldt,
Anis Khan,
Catherine Svabek ,
Josephine M. McAuliffe ,
Daniel Wrapp ,
Nita K. Patel ,
Kimberly E. Cook,
Bettina W. M. Richter,
Patricia C. Ryan
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
Development of a highly potent anti-RSV monoclonal antibody with extended half-life intended to be used as RSV prophylaxis for all infants.